


Amolyt Pharma obtient la désignation de médicament orphelin de la FDA pour l’AZP-3601 pour le traitement potentiel de l’hypoparathyroïdie

Advent France Biotechnology crée Gamut Therapeutics et finance son amorçage

Amolyt Pharma lance une collaboration de recherche avec PeptiDream

Domain Therapeutics launches Phase 1-enabling studies on proprietary EP4 receptor antagonist program in cancer immunotherapy

Yposkesi welcomes Brian Mullan, PhD, as director of innovation, analytical and process development

Genoscience Pharma completes successful phase 1b trial evaluating GNS561, PPT-1 inhibitor, in patients with primary and secondary liver cancer

PhysioStim appoints Dr. Bruno Le Grand as scientific advisor

Minoryx’s preclinical data for leriglitazone in Friedreich’s Ataxia published in Neurobiology of Disease Journal
